Preclinical studies of sex differences: a clinical perspective

Rhonda Voskuhl

Abstract
The new policy from the National Institutes of Health to encourage grant applicants to consider studying both females and males in preclinical biological experiments has been met with support and opposition. Here, we will discuss implications of preclinical studies of sex differences on clinical research.

Keywords: Sex differences, Translational research, National Institutes of Health

Letters to the Editor
It is now over a year since the announcement of a new National Institutes of Health (NIH) policy to encourage applicants to consider studying both females and males in preclinical biological experiments. The policy would prevent researchers from assuming no sex difference or ignoring one sex entirely [1]. Implementation of this policy is now beginning. It has been supported by some [2], while others oppose [3]. Should all researchers be expected to assess for sex differences [4]? Here, I offer a clinical perspective.

Sex differences in health and disease are numerous. There are sex differences in neurodegenerative, cardiovascular, and autoimmune diseases, to name a few [5]. Clinical observations of sex differences in disease should be viewed as precious clues in the search for new treatments to protect from disease, since they are naturally occurring disease modifiers [6]. Preclinical research on animals is essential for disentangling various mechanisms underlying sex differences in human diseases, revealing candidate targets for ultimate translation back to humans in a "bedside to bench to bedside" approach. We have recently employed this strategy to investigate the protective effects of an estrogen treatment in women with multiple sclerosis [7].

Arguments against basic biological research on sex differences in animals have included the idea that cells studied in the culture dish do not function like cells in the human body and that mice differ from humans [3]. However, those limitations are true for all preclinical research, not just sex differences. No preclinical model perfectly simulates all aspects of human disease. Each model is chosen based on a specific question, and several different models are used to provide comprehensive insight. Why should the study of the biology of sex differences be held to a different standard?

Another rationale for not doing biological sex differences research has been that there are gender-related social factors in humans that are poorly modeled in preclinical research [3]. Most clinical observations in humans are the result of both biological and social factors, nature and nurture. There are social and cultural differences affiliated with age and race. Does this preclude the study of biological effects of aging or race? No. Sex, age, and race are each important variables that impact disease, and understanding both the biological and social factors is needed for optimal treatments in each population.

Let us now look beyond the first step the NIH has proposed that encourages researchers to consider sex as a biological variable in their systems. In the years ahead, this will result in many new observations of sex differences. When you look, you find. But to show that sex differences exist is the beginning, not the end. A second step is needed. Support for research to understand the mechanistic basis for observed sex differences will be required to capitalize on initial observations and translate them back to human disease. If step one is taken without step two, a bottleneck of observations regarding sex differences.
differences will accumulate. Both steps are needed for ultimate translation back to the clinic.

In summary, an inconvenient truth for some seems to be that biological sex differences exist in many systems. Speaking as a feminist, sex differences do not imply inequality of the sexes. Speaking as a scientist, knowledge is always the path forward. Speaking as a physician, how can we justify ignoring a major disease modifier to patients? Rather, we must embrace the study of sex differences without political bias or fear of misinterpretation in the pursuit of health for man- and womankind.

Abbreviations
NIH: National Institutes of Health.

Competing interests
Dr. Voskuhl is an inventor on a UCLA patent for estriol use in multiple sclerosis.

Author’s contributions
RV conceived of and wrote the manuscript and is accountable for all aspects of the work.

Author’s information
Dr. Voskuhl is a clinician researcher who focuses on preclinical models to understand the mechanism of sex differences in multiple sclerosis then translates basic research findings into the design and implementation of clinical trials in patients with multiple sclerosis.

Acknowledgements
The author wishes to thank the Conrad N. Hilton Foundation (grant #20150232) and the National Institutes of Health (grant #R01NS0515910), as well as the Tom Sherak MS Hope Foundation, the California Community Foundation, and the Jack H. Skirball Foundation for their financial support. The funding agencies had no role in the writing or the decision to submit the manuscript.

Received: 5 January 2016 Accepted: 18 January 2016

References
1. Clayton JA, Collins FS. Policy: NIH to balance sex in cell and animal studies. Nature. 2014;509(7500):282–3.
2. Klein SL, Schiebinger L, Stefanick ML, Cahill L, Danska J, de Vries GJ, et al. Opinion: sex inclusion in basic research drives discovery. Proc Natl Acad Sci U S A. 2015;112(17):5257–8.
3. Richardson SS, Reiches M, Shattuck-Holden H, LaBorte ML, Consoli T. Opinion: focus on preclinical sex differences will not address women’s and men’s health disparities. Proc Natl Acad Sci U S A. 2015;112(44):13419–20.
4. Clayton JA. Studying both sexes: a guiding principle for biomedicine. FASEB J. 2015;29.
5. Whitacre CC, Reingold SC, O’Loneey PA. A gender gap in autoimmunity. Science. 1999;283(5406):1277–8.
6. Voskuhl RR, Gold SM. Sex-related factors in multiple sclerosis susceptibility and progression. Nat Rev Neurol. 2012;8(5):255–63.
7. Voskuhl RR, Wang H, Wu TC, Scottie NL, Nakamura K, Kurth F, et al. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(1):35–46.